Additionally, because of the drug’s consumption in the peripheral blood and its poor ability to enter the bone marrow tissues, high levels of CD33 tumor burden in the peripheral blood also confer resistance to the treatment and are linked to worse results. Here, CD33 is linked to neoplasm.